DigitalBDinc

$GNPX Financial News finance.yahoo.com/quote/GNPX/pre… Positive clinical data on biomarkets in patients receiving Reqorsa Gene Therapy finance.yahoo.com/sectors/health… Presents positive preclinical data on Type 2 diabetes gene therapy at ASGCT finance.yahoo.com/sectors/health… Patent granted finance.yahoo.com/sectors/health… Presents positive preclinical data on Reqorsa gene therapy at AACR finance.yahoo.com/sectors/health… To present positive pre-clinical data on Reqorsa gene therapy for lung cancer at AACR annual meeting finance.yahoo.com/news/genprex-c… Reqorsa patent grants in Japan and Europe finance.yahoo.com/news/genprex-s… Reverse split leaves only 9M shares issued. Low float and heavily shorted. Split adjusted data here digitalbdinc.com/images/gnpxstr… AI report identifies up to 30X undervaluation digitalbdinc.com/report/gnpxdee… Positive preliminary preclinical data in Type 2 diabetic animal study of GPX-002 finance.yahoo.com/news/genprex-a… 8-K filing shows Company believes it has the stockholder's equity from recent raises to meet NASDAQ mininmum listing requirements sec.gov/ix?doc=/Archiv… Adds clincial trial site for Acclaim-1 and Acclaim-3 lung cancer trials finance.yahoo.com/news/genprex-a… Acclaim-1 Phase 1 gene therapy clinical trial data published in Clinical Lung Cancer journal finance.yahoo.com/news/data-genp… Positive preclinical data on use of Reqorsa gene therapy for lung cancer finance.yahoo.com/news/genprex-c… Patent issued for Requorsa combined with PD-L1 antibodies finance.yahoo.com/news/genprex-a… European patent office intent to grant patent for combination of Reqorsa gene therapy and PD-1 antibodies finance.yahoo.com/news/genprex-a… Deck genprex.com/wp-content/upl… Web genprex.com Publicity for this report paid for by the Company.

@genprex Positive biomarker data published (Trop-2 H-scores 100+, PTEN scores below 100). Encouraging Type 2 diabetes gene therapy. Demonstrates in vivo proof-of-concept for novel diabetes gene therapy. Rejuvenated exhausted beta cells and normalized glucose levels. See links:

$WGRX Financial News finance.yahoo.com/quote/WGRX/pre… Q1 results finance.yahoo.com/sectors/health… Accelerates digital health expansion finance.yahoo.com/sectors/health… Pilot MSO collaboration with Kare PharmTech targeting $14B CCM and RPM services market finance.yahoo.com/news/wellgisti… Joint venture with Kare PharmaTech finance.yahoo.com/sectors/health… Shorts exposed digitalbdinc.com/news/wgrxpr4-7… Report digitalbdinc.com/reports/wgrx4-… Squeeze starts at $0.61 digitalbdinc.com/images/wgrxstr… Shareholder Letter finance.yahoo.com/news/wellgisti… Targets $70B market addressing muscle loss from weight loss therapies finance.yahoo.com/news/wellgisti… Fact Sheet wellgisticshealth.com/wp-content/upl… Deck wellgisticshealth.com/wp-content/upl… Web wellgisticshealth.com Publicity for this report paid for by the Company.

@WGRX_Health Q1 revs near $1M with Q2 guidance of $1.77M . Expands direct sales with focus on $70B market for muscle loss from glp weight loss products. Kare joint venture expands access to 200,000+. EinsteinRx Ai platform optimizes dispensing and patient outcomes. Links below:

$RIME Financial News finance.yahoo.com/quote/RIME/pre… Expanded contract with P&G India finance.yahoo.com/markets/stocks… Record Q1 results. Revs +71% from last quarter and +1,851% YOY finance.yahoo.com/markets/stocks… $12M annualized revenue run rate finance.yahoo.com/markets/stocks… 45.65% of all trading volume is short selling. Squeeze starts at $1.99 digitalbdinc.com/images/rimestr… SemiCab whitepaper cdn.prod.website-files.com/695ca8537e49ad… Deck cdn.prod.website-files.com/695ca8537e49ad… Web algoholdings.com Publicity for this report paid for by the Company

@Algorhythm_AI Q1 results are off to a strong start with first quarter revenue growing more than 71% sequentially and more than 1,800% year-over-year as SemiCab business continues to scale. Apex SaaS platform positioned strong growth. Links in thread:

$NXXT Financial News finance.yahoo.com/quote/NXXT/pre… Q1 earnings call today at 9am EDT event.choruscall.com/mediaframe/web… Q1 results. Revs +29% YOY to $21.1M, gross profit more than tripled and interest expense decreased by 80% YOY finance.yahoo.com/sectors/energy… One of most promising renewable energy stories finance.yahoo.com/sectors/energy… Launches one of nation's largest last-mile mobile fuel delivery stations finance.yahoo.com/sectors/energy… Ai-driven dashboard for integrated energy ecosystem finance.yahoo.com/news/nextnrg-i… Expands fleet in highest-margin markets and advances microgrid pipeline finance.yahoo.com/sectors/energy… Ai Deep Research Report with $6.30PT digitalbdinc.com/report/nxxtdee… Simply Wallst report with $5.50PT simplywall.st/community/narr… 48% of all trading volume shorted. Squeeze starts at $2.04 digitalbdinc.com/images/nxxtstr… NeutronX partnership focuses on federal energy and defense infrastructure projects finance.yahoo.com/news/neutronx-… Microgrid operating model nextnrg.com/blog/co-locati… Power generation, storage, electronics and software working together to power microgrids nextnrg.com/blog/building-… Deck assets.thevendorgroup.com/site/a52bc87d-… Web nextnrg.com Publicity for this report paid for by the Company

@NextNRGinc Q1 results. $21.1M in revs, gross profit triples. Earnings call today at 9am EDT. Ai-powered microgrids respond to disruptions and offer autonomous distributed balanced generation while optimizing for cost and resilience. Links below:

$JSDA Financial News finance.yahoo.com/quote/JSDA/pre… Q1 results. Revs $12.4M (+194% yoy), gross profit +179% to $3.9M. Raises 2026 full year revenue guidance to $40M+ finance.yahoo.com/markets/stocks… Expands product offerings in 650 top-volume stores nationwide finance.yahoo.com/markets/stocks… Expands Canadian distribution through 700 Circle K stores finance.yahoo.com/news/jones-sod… Expands Fallout beverage platform with national club store rollout finance.yahoo.com/markets/stocks… Expanded Costco program increases Q4 momentum finance.yahoo.com/news/jones-sod… Squeeze starts at $0.74 digitalbdinc.com/images/jsdastr… Shorts exposed digitalbdinc.com/news/jsdapr1-1… Report digitalbdinc.com/reports/jsda1-… Bolsters C-Suite with proven business leaders finance.yahoo.com/news/jones-sod… Fallout-themed Vault-Tec Supply Packs at select Costco Warehouse Clubs finance.yahoo.com/news/jones-sod… Expands in Southeast with additional Costco launch finance.yahoo.com/news/jones-sod… Web jonessoda.com Publicity for this report paid for by the Company.

@jonessodaco Q1 results. Revs $12.4M (+194% yoy), gross profit +179% to $3.9M. Raises 2026 full year revenue guidance to $40M+. Expands Costco , CircleK and Walmart national and international distribution. Squeeze starts at $0.74. Links below:

$GTBP Financial News finance.yahoo.com/quote/GTBP/pre… Q1 results finance.yahoo.com/sectors/health… 1st patient dosed in Phase 1 trial of GTB-5550, a B7-H2 targeted NK cell engage for solid tumors finance.yahoo.com/sectors/health… Full year 2025 results finance.yahoo.com/news/gt-biopha… FDA clearance of IND application for GTB-5550 finance.yahoo.com/news/gt-biopha… Advances Phase I trials finance.yahoo.com/news/gt-biopha… Q3 results finance.yahoo.com/news/gt-biopha… GTB-3650 advances Phase 1 trial to Cohort 4 following safety review of Cohort 3 finance.yahoo.com/news/gt-biopha… Reports progress in Phase 1 trial of lead candidate for blood cancers finance.yahoo.com/news/exclusive… Shorts exposed digitalbdinc.com/images/gtbpstr… Ai-powered Deep Research report $15.00 PT digitalbdinc.com/report/gtbpdee… Roth/MKM $11.00 PT digitalbdinc.com/report/gtbprot… Deck gtbiopharma.com/corporate-pres… Web gtbiopharma.com Publicity for this report paid for by the Company.

@GTBiopharma 1st human dosing. Advances 3 TriKE candidates. Platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034. Links

$GTBP Financial News finance.yahoo.com/quote/GTBP/pre… 1st patient dosed in Phase 1 trial of GTB-5550, a B7-H2 targeted NK cell engage for solid tumors finance.yahoo.com/sectors/health… Full year 2025 results finance.yahoo.com/news/gt-biopha… FDA clearance of IND application for GTB-5550 finance.yahoo.com/news/gt-biopha… Advances Phase I trials finance.yahoo.com/news/gt-biopha… Q3 results finance.yahoo.com/news/gt-biopha… GTB-3650 advances Phase 1 trial to Cohort 4 following safety review of Cohort 3 finance.yahoo.com/news/gt-biopha… Reports progress in Phase 1 trial of lead candidate for blood cancers finance.yahoo.com/news/exclusive… Shorts exposed digitalbdinc.com/images/gtbpstr… Ai-powered Deep Research report $15.00 PT digitalbdinc.com/report/gtbpdee… Roth/MKM $11.00 PT digitalbdinc.com/report/gtbprot… Deck gtbiopharma.com/corporate-pres… Web gtbiopharma.com Publicity for this report paid for by the Company.

@GTBiopharma $GTBP 1st human dosing. Advanced TriKE next-generation platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034

$NXPL Financial News finance.yahoo.com/quote/NXPL/pre… $9.9 Million in Revenue for Q1 2026 with Record Quarterly Consolidated Gross Margins of 35% ir.nextplat.com/news-events/pr… Expects Q1 gross margins to jump to 34%+ ir.nextplat.com/news-events/pr… Regains full NASDAQ compliance finance.yahoo.com/markets/stocks… Deploys PharmcoRX AI-powered presciption processing finance.yahoo.com/sectors/health… $400k IoT contract brings military Q1'26 pipeline to $1.2M ir.nextplat.com/news-events/pr… Full year earnings results finance.yahoo.com/sectors/health… Launches 50 state nationwide fulfillment capabilities ir.nextplat.com/news-events/pr… $820,000 Global Telesat contract award finance.yahoo.com/news/nextplats… Expects $55M in 2025 revenues and higher margins in 2026 finance.yahoo.com/news/nextplat-… Shorts exposed digitalbdinc.com/news/nxplpr3-9… Report digitalbdinc.com/reports/nxpl3-… Squeeze starts at $13.52 digitalbdinc.com/images/nxplstr… International expansion finance.yahoo.com/news/nextplats… Expands 5G and AI powered IOT through new Telit Cinterion agreement finance.yahoo.com/news/nextplats… Deck d1io3yog0oux5.cloudfront.net/_b7ec68f9196ae… Web nextplat.com Publicity for this report paid for by the Company.

@nextplat Q1 revs $9.9M with record 35% gross margins vs 21% in prior year. Reduces expenses 9%. Expects positive net income in 2nd half. $54.3M full year 2025 revs, 340B covered entities, higher margin fulfillment exceeding 6,000+ scripts per month. Links below:

$MBRX Financial News finance.yahoo.com/quote/MBRX/pre… MIRACLE Trial unblinding imminent as blinded data continues to significantly outperform historical benchmarks finance.yahoo.com/news/moleculin… Cleveland Clinic finds no clinically significant cardiotoxicity with Annamycin in R/R AML patients finance.yahoo.com/sectors/health… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

@moleculinbio Trial unblinding imminent. ClevelandClinic finds no significant cardiotoxicity. Extends survival by more than 60% in metastatic pancreatic cancer pre-clin models. If mid '26 results of 45 person cohort confirms 40% CRc rate, risk drops. Links below:

$WGRX Financial News finance.yahoo.com/quote/WGRX/pre… Pilot MSO collaboration with Kare PharmTech targeting $14B CCM and RPM services market finance.yahoo.com/news/wellgisti… Joint venture with Kare PharmaTech finance.yahoo.com/sectors/health… Shorts exposed digitalbdinc.com/news/wgrxpr4-7… Report digitalbdinc.com/reports/wgrx4-… Squeeze starts at $0.89 digitalbdinc.com/images/wgrxstr… LOI to potentially acquire Neuritek Therapeuics for $105M finance.yahoo.com/sectors/health… Shareholder Letter finance.yahoo.com/news/wellgisti… Targets $70B market addressing muscle loss from weight loss therapies finance.yahoo.com/news/wellgisti… Fact Sheet wellgisticshealth.com/wp-content/upl… Deck wellgisticshealth.com/wp-content/upl… Web wellgisticshealth.com Publicity for this report paid for by the Company.

@WGRX_Health Targets $14B market with new collab. Kare joint venture expands access to 200,000+. $105M letter of intent to acquire Neuritek. Targets $70B market for muscle loss due to weight loss products. EinsteinRx Ai platform to optimize dispensing and patient outcomes. Links

$MBRX Financial News finance.yahoo.com/quote/MBRX/pre… MIRACLE Trial unblinding imminent as blinded data continues to significantly outperform historical benchmarks finance.yahoo.com/news/moleculin… Cleveland Clinic finds no clinically significant cardiotoxicity with Annamycin in R/R AML patients finance.yahoo.com/sectors/health… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

@moleculinbio Trial unblinding imminent. @ClevelandClinic finds no significant cardiotoxicity. Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models. If mid '26 results of 45-patient cohort confirms 40% CRc rate, clinical risk drops.

$MBRX Financial News finance.yahoo.com/quote/MBRX/pre… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

@moleculinbio Secures additional strategic patent. Solid intellectual property protection globally ahead of pending Phase 3 data release. Links below:

@moleculinbio $MBRX Financial News finance.yahoo.com/quote/MBRX/pre… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

Secures additional strategic patent. Solid intellectual property protection across four continents ahead of pending Phase 3 data release. Links below:

@moleculinbio $MBRX Financial News finance.yahoo.com/quote/MBRX/pre… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

$MBRX Financial News finance.yahoo.com/quote/MBRX/pre… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

@moleculinbio Secures additional strategic patent. Solid intellectual property protection across four continents ahead of pending Phase 3 data release. Links below:

$MBRX Financial News finance.yahoo.com/quote/MBRX/pre… Secures additional strategic patent moleculin.com/moleculin-biot… Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models finance.yahoo.com/sectors/health… Ai powered Deep Research Report shows potential valuation upside digitalbdinc.com/report/mbrxdee… Hits enrollment milestone triggering countdown to mid-2026 trail data readout finance.yahoo.com/sectors/health… FY 2025 results and confirmation of mid-2026 interim data release finance.yahoo.com/sectors/health… Trial delivers 40% preliminary blinded CRc rate (n=30) finance.yahoo.com/news/moleculin… Patent allowance in Japan for Annamycin finance.yahoo.com/news/moleculin… Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects finance.yahoo.com/news/moleculin… Shorts exposed digitalbdinc.com/images/mbrxstr… Deck d2ghdaxqb194v2.cloudfront.net/2705/199847.pdf Web moleculin.com Publicity for this report paid for by the Company.

Secures additional strategic patent. Annamycin extends survival by more than 60% in metastatic pancreatic cancer models. If mid '26 unblinding of 45-person cohort confirms 40% CRc rate, risk drops. Links below:

$CRDL Financial News finance.yahoo.com/quote/CRDL/pre… Phase 2 Maveric results accepted for publication in Journal of American Heart Association cardiolrx.com/cardiol-therap… Expands MAVERIC Phase III trial in the US finance.yahoo.com/sectors/health… CardiolRx shows Myocarditis promise finance.yahoo.com/sectors/health… Squeeze starts at $1.39 digitalbdinc.com/images/crdlstr… Canaccord $8.00 PT digitalbdinc.com/report/crdlcan… FY 2025 results finance.yahoo.com/sectors/health… ARCHER Phase 2 study results published in ESC Heart Failure finance.yahoo.com/news/cardiol-t… 50% enrollment in Phase 3 MAVERIC trial in recurrent pericarditis finance.yahoo.com/news/cardiol-t… Leede $11.00PT digitalbdinc.com/report/crdllee… Roth $10.00PT digitalbdinc.com/report/crdlrot… HC Wainwright $9.00PT digitalbdinc.com/report/crdlhcw… Deck cardiolrx.com/wp-content/upl… Web cardiolrx.com Publicity for this report paid for by the Company.

@CardiolRx Phase 2 Maveric results accepted for publication in JAHA. Expands Phase 3 trial network. Positive Phase 2 Archer data in acute myocarditis. Advances CRD-38 program, a novel next generation therapy intended for use in heart failure. Broad patents. See links

$AMZE Financial News finance.yahoo.com/quote/AMZE/pre… Partners with All Media Solutions to power brand supply for Amaze Live finance.yahoo.com/markets/stocks… LOI with Digital Innovations to integrate IRMA engine to expand creator and fan monetization finance.yahoo.com/markets/stocks… 20 brands commit inventory to Amaze Live shopping finance.yahoo.com/markets/stocks… Launches next-generation multi-channel live shopping platform finance.yahoo.com/markets/stocks… Get early access to Amaze Live shopping amaze.co/amazelive Launches Creator Commerce media platform finance.yahoo.com/markets/stocks… Previews new product launch of Amaze Commerce finance.yahoo.com/sectors/techno… Shareholder update finance.yahoo.com/markets/stocks… Amaze and LA Times Studios launch Food Channel LA, a creator-led commerce platform finance.yahoo.com/markets/articl… Shorts exposed digitalbdinc.com/news/amzepr3-2… Report digitalbdinc.com/reports/amze3-… Ladenburg Thalmann $3.00PT digitalbdinc.com/report/amzelad… Squeeze starts at $1.04 digitalbdinc.com/images/amzestr… Investor Summit presentation March 25th 9am EDT investorsummitgroup.com/landing-page/a… Expanded live shopping capabilities for creators finance.yahoo.com/sectors/techno… Launches proprietary programmtic advertising platform finance.yahoo.com/news/amaze-ann… Partners with OpenWav.ai to provide customizable Plushies for creators finance.yahoo.com/news/amaze-exp… Deck ir.amaze.co/_assets/_c9557… Web amaze.co Publicity for this report paid for by the Company.

Amaze partners with All Media Solutions for live shopping. Announces Creator Commerce media platform. Billions of visits and millions of stores, data has become key value creator. Launches creator-led Food Channel commerce platform with @LATimes. Links below:

THREAD $XXII Financial News finance.yahoo.com/quote/XXII/pre… 2026 vision for VLN product growth finance.yahoo.com/sectors/health… New testing services agreement finance.yahoo.com/sectors/health… Targets half of $82B US market with 100mm VLN product initiative finance.yahoo.com/sectors/health… Q4 results finance.yahoo.com/markets/stocks… Shorts exposed digitalbdinc.com/images/xxiistr… Only combustible product authorized by FDA to specifically address cessation finance.yahoo.com/news/22nd-cent… Emerging Growth issues updated report finance.yahoo.com/news/emerging-… Emerging Growth report $9.00PT emerginggrowth.com/wp-content/upl… Secures $9.5 million in proceeds from insurance claim settlement finance.yahoo.com/news/22nd-cent… Debt free balance sheet and new growth capital finance.yahoo.com/news/22nd-cent… Growing list of state authorizations finance.yahoo.com/news/22nd-cent… Multiple brands partner to expand availability and awareness of VLN products finance.yahoo.com/news/vln-comme… Deck 1347858.ir365connect.com/assets/1347858… Publicity for this report paid for by the Company.

@_xxiicentury Corporate update outlines vision for low nic alternative. Multiple scientific studies demonstrate merits of products. Non-addictive alternative in the fight against the harms of inhaled combustibles. Links in thread:

$IBG Financial News finance.yahoo.com/quote/IBG/pres… Completes independent reserve report and multi-phase development plan finance.yahoo.com/sectors/energy… Shorts exposed digitalbdinc.com/news/ibgpr4-21… Report digitalbdinc.com/reports/ibg4-2… 39.38% of all trading volume is short selling digitalbdinc.com/images/ibgstr5… BlockFuel Energy merger update finance.yahoo.com/news/innovatio… BlockFuel Energy merger finance.yahoo.com/news/innovatio… Completes $6M raise feeds.issuerdirect.com/news-release.h… Deck irp.cdn-website.com/5f9ea1c4/files… Web innovationbev.com Publicity for this report paid for by the Company.

IBG + BlockFuel Energy plan 8 new vertical wells this year and up to 20 by 2028. 15 producing wells and 5 in the process of completing reactivation. Production levels are expected to increase as additional wells return to service. Short positions being surveilled daily. See links